GB0130007D0 - Screening method for agents useful in treating diabetes - Google Patents
Screening method for agents useful in treating diabetesInfo
- Publication number
- GB0130007D0 GB0130007D0 GBGB0130007.8A GB0130007A GB0130007D0 GB 0130007 D0 GB0130007 D0 GB 0130007D0 GB 0130007 A GB0130007 A GB 0130007A GB 0130007 D0 GB0130007 D0 GB 0130007D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- activity
- pai
- diabetes
- screening method
- agents useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8132—Plasminogen activator inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods for screening agents effective against diabetes or preventing the onset of diabetes, in particular Type 2 diabetes, are provided. In one aspect of the invention, the method encompasses assaying for PAI-1 activity in the presence of a candidate agent; and correlating a decrease in PAI-1 activity relative to when the candidate agent is absent with the presence of a potential agent effective against diabetes. Alternatively, E2F activity is detected, an increase in E2F activity reflecting a decrease in PAI-1 activity. Also provided are methods for inhibiting PAI-1 activity, pharmaceutical agents and compositions.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0130007.8A GB0130007D0 (en) | 2001-12-14 | 2001-12-14 | Screening method for agents useful in treating diabetes |
JP2003552991A JP2005512546A (en) | 2001-12-14 | 2002-12-13 | Method for screening drug useful for treatment of diabetes |
PCT/EP2002/014233 WO2003052124A2 (en) | 2001-12-14 | 2002-12-13 | Screening method for agents useful in treating diabetes |
DE60220185T DE60220185D1 (en) | 2001-12-14 | 2002-12-13 | SCREENING METHOD FOR SUBSTANCES FOR THE TREATMENT OF DIABETES |
AT02804896T ATE362545T1 (en) | 2001-12-14 | 2002-12-13 | SCREENING PROCEDURE FOR SUBSTANCES FOR THE TREATMENT OF DIABETES |
US10/498,587 US20050037956A1 (en) | 2001-12-14 | 2002-12-13 | Screening method for agents useful in treating diabetes |
AU2002366442A AU2002366442A1 (en) | 2001-12-14 | 2002-12-13 | Screening method for agents useful in treating diabetes |
EP02804896A EP1458883B1 (en) | 2001-12-14 | 2002-12-13 | Screening method for agents useful in treating diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0130007.8A GB0130007D0 (en) | 2001-12-14 | 2001-12-14 | Screening method for agents useful in treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0130007D0 true GB0130007D0 (en) | 2002-02-06 |
Family
ID=9927673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0130007.8A Ceased GB0130007D0 (en) | 2001-12-14 | 2001-12-14 | Screening method for agents useful in treating diabetes |
Country Status (8)
Country | Link |
---|---|
US (1) | US20050037956A1 (en) |
EP (1) | EP1458883B1 (en) |
JP (1) | JP2005512546A (en) |
AT (1) | ATE362545T1 (en) |
AU (1) | AU2002366442A1 (en) |
DE (1) | DE60220185D1 (en) |
GB (1) | GB0130007D0 (en) |
WO (1) | WO2003052124A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771720B2 (en) * | 2007-09-07 | 2010-08-10 | Cisthera, Inc. | Humanized PAI-1 antibodies |
US7981415B2 (en) * | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001074793A2 (en) * | 2000-04-03 | 2001-10-11 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
-
2001
- 2001-12-14 GB GBGB0130007.8A patent/GB0130007D0/en not_active Ceased
-
2002
- 2002-12-13 DE DE60220185T patent/DE60220185D1/en not_active Expired - Lifetime
- 2002-12-13 WO PCT/EP2002/014233 patent/WO2003052124A2/en active IP Right Grant
- 2002-12-13 JP JP2003552991A patent/JP2005512546A/en active Pending
- 2002-12-13 AT AT02804896T patent/ATE362545T1/en not_active IP Right Cessation
- 2002-12-13 EP EP02804896A patent/EP1458883B1/en not_active Expired - Lifetime
- 2002-12-13 AU AU2002366442A patent/AU2002366442A1/en not_active Abandoned
- 2002-12-13 US US10/498,587 patent/US20050037956A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002366442A8 (en) | 2003-06-30 |
JP2005512546A (en) | 2005-05-12 |
WO2003052124A2 (en) | 2003-06-26 |
EP1458883B1 (en) | 2007-05-16 |
DE60220185D1 (en) | 2007-06-28 |
US20050037956A1 (en) | 2005-02-17 |
ATE362545T1 (en) | 2007-06-15 |
EP1458883A2 (en) | 2004-09-22 |
AU2002366442A1 (en) | 2003-06-30 |
WO2003052124A3 (en) | 2003-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9908280A (en) | Phospholipase enzyme inhibitors | |
EE200000522A (en) | Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity | |
DK1091975T3 (en) | New cyclosporine with improved activity profile | |
AP2004003189A0 (en) | Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents. | |
DE69737592D1 (en) | MEDIUM AGAINST JUCKREIZ | |
CL2004001174A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING: 1- (4-FLUOROPHENYL) -3 (R) - [3- (4-FLUOROPHENYL) -3 (S) -HYDROXIPROPIL] -4 (S) - (4-HYDROXIFENYL) -2-ACETIDINONE ( EZETIMIBA) AND EXCIPIENTS; AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROSIS, HIPERCOLESTEROLEMIA, DAY | |
ITRM990338A0 (en) | DIETARY OR PHARMACEUTICAL COMPOSITION USEFUL FOR THE PREVENTION OR TREATMENT OF HYPEROXALURIA. | |
ATE287402T1 (en) | NANOMOLAR, NON-PEPTIDIC INHIBITORS OF CATHEPSIN D | |
EE04356B1 (en) | aP2 inhibitor for use in the treatment of diabetes and a pharmaceutical composition comprising it | |
ATE268750T1 (en) | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | |
BR9909819A (en) | Amide, use of amides, and, pharmaceutical preparation for oral, parenteral or intraperitoneal use | |
WO2000034511A3 (en) | Aβ-PEPTIDE SCREENING ASSAY | |
BR9901058A (en) | N-cail and n-aroyl aralkyl amides. | |
ITMI981903A0 (en) | IMMONOLOGICAL MATERIALS AND METHODS FOR THE DETECTION OF DIHYDROPYRIMIDINE DEHYDROGNASE | |
ATE201204T1 (en) | DERIVATIVES OF THIAZOLIDINE-4-CARBONIC ACID AS CYTOPROTECTIVE AGENTS | |
IL133004A0 (en) | Pharmaceutical compositions comprising an aldose inhibitor and an ace inhibitor | |
TR200101493T2 (en) | Eletriptan hydrobromide monohydrate | |
EP0880964A3 (en) | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | |
AU2002366442A8 (en) | Screening method for agents useful in treating diabetes | |
WO2001087239A3 (en) | Methods of affecting laminin 5 processing | |
DE69710193D1 (en) | 6-Substituted amino-4-oxa-1-azabicyclo [3.2.0] heptan-7-one derivatives as cysteine protease inhibitors | |
FR2786398B1 (en) | ANTI-CANCER AND ANTI-CHEMORESISTANCE PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CANCER AGENT AND AT LEAST ONE PEPTIDE | |
IT1313870B1 (en) | DRILLING AND MILLING MACHINE, PARTICULARLY DESIGNED FOR THE PROCESSING OF PANELS AND SIMILAR. | |
BR0316544A (en) | Calcally Compounds | |
NZ514691A (en) | Method to type prion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |